Browse AGER

Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Secreted.; SUBCELLULAR LOCATION: Isoform 10: Cell membrane Single-pass type I membrane protein
Domain PF08205 CD80-like C2-set immunoglobulin domain
PF00047 Immunoglobulin domain
PF13895 Immunoglobulin domain
Function

Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001906 cell killing
GO:0001909 leukocyte mediated cytotoxicity
GO:0001910 regulation of leukocyte mediated cytotoxicity
GO:0001913 T cell mediated cytotoxicity
GO:0001914 regulation of T cell mediated cytotoxicity
GO:0002246 wound healing involved in inflammatory response
GO:0002248 connective tissue replacement involved in inflammatory response wound healing
GO:0002250 adaptive immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0007159 leukocyte cell-cell adhesion
GO:0007254 JNK cascade
GO:0010001 glial cell differentiation
GO:0010469 regulation of receptor activity
GO:0014002 astrocyte development
GO:0021782 glial cell development
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0031098 stress-activated protein kinase signaling cascade
GO:0031341 regulation of cell killing
GO:0031348 negative regulation of defense response
GO:0032102 negative regulation of response to external stimulus
GO:0032103 positive regulation of response to external stimulus
GO:0032602 chemokine production
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032642 regulation of chemokine production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032693 negative regulation of interleukin-10 production
GO:0032722 positive regulation of chemokine production
GO:0032735 positive regulation of interleukin-12 production
GO:0032872 regulation of stress-activated MAPK cascade
GO:0032874 positive regulation of stress-activated MAPK cascade
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033674 positive regulation of kinase activity
GO:0034103 regulation of tissue remodeling
GO:0034104 negative regulation of tissue remodeling
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0036293 response to decreased oxygen levels
GO:0040017 positive regulation of locomotion
GO:0042063 gliogenesis
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042104 positive regulation of activated T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043506 regulation of JUN kinase activity
GO:0043507 positive regulation of JUN kinase activity
GO:0045785 positive regulation of cell adhesion
GO:0045860 positive regulation of protein kinase activity
GO:0046006 regulation of activated T cell proliferation
GO:0046328 regulation of JNK cascade
GO:0046330 positive regulation of JNK cascade
GO:0046631 alpha-beta T cell activation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046651 lymphocyte proliferation
GO:0048708 astrocyte differentiation
GO:0048771 tissue remodeling
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050727 regulation of inflammatory response
GO:0050728 negative regulation of inflammatory response
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0050930 induction of positive chemotaxis
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051091 positive regulation of sequence-specific DNA binding transcription factor activity
GO:0051092 positive regulation of NF-kappaB transcription factor activity
GO:0051098 regulation of binding
GO:0051101 regulation of DNA binding
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0051403 stress-activated MAPK cascade
GO:0061041 regulation of wound healing
GO:0061045 negative regulation of wound healing
GO:0070302 regulation of stress-activated protein kinase signaling cascade
GO:0070304 positive regulation of stress-activated protein kinase signaling cascade
GO:0070482 response to oxygen levels
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:0071605 monocyte chemotactic protein-1 production
GO:0071637 regulation of monocyte chemotactic protein-1 production
GO:0071639 positive regulation of monocyte chemotactic protein-1 production
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0072657 protein localization to membrane
GO:0090594 inflammatory response to wounding
GO:0097028 dendritic cell differentiation
GO:0097709 connective tissue replacement
GO:1902105 regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1903034 regulation of response to wounding
GO:1903035 negative regulation of response to wounding
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903706 regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1904596 regulation of connective tissue replacement involved in inflammatory response wound healing
GO:1904597 negative regulation of connective tissue replacement involved in inflammatory response wound healing
GO:1904603 regulation of advanced glycation end-product receptor activity
GO:1904604 negative regulation of advanced glycation end-product receptor activity
GO:1905203 regulation of connective tissue replacement
GO:1905204 negative regulation of connective tissue replacement
GO:2000272 negative regulation of receptor activity
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2001198 regulation of dendritic cell differentiation
GO:2001200 positive regulation of dendritic cell differentiation
Molecular Function GO:0005539 glycosaminoglycan binding
GO:0008201 heparin binding
GO:0044548 S100 protein binding
GO:1901681 sulfur compound binding
GO:1904599 advanced glycation end-product binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-166054: Activated TLR4 signalling
R-HSA-879415: Advanced glycosylation endproduct receptor signaling
R-HSA-1834949: Cytosolic sensors of pathogen-associated DNA
R-HSA-3134963: DEx/H-box helicases activate type I IFN and inflammatory cytokines production
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-975871: MyD88 cascade initiated on plasma membrane
R-HSA-975155: MyD88 dependent cascade initiated on endosome
R-HSA-166166: MyD88-independent TLR3/TLR4 cascade
R-HSA-166058: MyD88
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
R-HSA-1810476: RIP-mediated NFkB activation via ZBP1
R-HSA-445989: TAK1 activates NFkB by phosphorylation and activation of IKKs complex
R-HSA-168180: TRAF6 Mediated Induction of proinflammatory cytokines
R-HSA-933542: TRAF6 mediated NF-kB activation
R-HSA-975138: TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation
R-HSA-937061: TRIF-mediated TLR3/TLR4 signaling
R-HSA-168142: Toll Like Receptor 10 (TLR10) Cascade
R-HSA-181438: Toll Like Receptor 2 (TLR2) Cascade
R-HSA-168164: Toll Like Receptor 3 (TLR3) Cascade
R-HSA-166016: Toll Like Receptor 4 (TLR4) Cascade
R-HSA-168176: Toll Like Receptor 5 (TLR5) Cascade
R-HSA-168181: Toll Like Receptor 7/8 (TLR7/8) Cascade
R-HSA-168138: Toll Like Receptor 9 (TLR9) Cascade
R-HSA-168179: Toll Like Receptor TLR1
R-HSA-168188: Toll Like Receptor TLR6
R-HSA-168898: Toll-Like Receptors Cascades
R-HSA-1606322: ZBP1(DAI) mediated induction of type I IFNs
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AGER and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between AGER and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23269246Pancreatic ductal adenocarcinomaInhibit immunityTo study the role of RAGE expression in the setting of mutant Ras-promoted pancreatic carcinogenesis (KC), a triple-transgenic model of spontaneous murine PDA in a RAGE-null background (KCR) was generated. KCR mice also maintained a significantly less suppressive milieu evidenced by marked decreases in CCL22 in relation to CXCL10 and diminished serum levels of IL-6.
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AGER in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AGER in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.3920.14
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8230.0721
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.0890.859
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3330.208
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2360.884
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.0480.625
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1030.759
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.540.417
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.7770.256
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.480.706
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4530.79
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1860.0821
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AGER in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AGER. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AGER. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AGER.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AGER. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AGER expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AGER and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAGER
Nameadvanced glycosylation end product-specific receptor
Aliases RAGE isoform NtRAGE-delta; RAGE isoform sRAGE-delta; receptor for advanced glycation end-products variant 20 ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AGER collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.